Aurobindo Pharma Limited (AUROPHARMA) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹1,855.3 (+2.84% day change)
Key ratios
- P/E ratio
- 30.75
- P/B ratio
- 2
- ROE (%)
- 9.25
- ROCE (%)
- 12.55
- Debt/Equity
- 0.21
- Dividend yield (%)
- 0.31
- Market cap (₹ Cr)
- 106,749.86
Forensic checks
Piotroski F-Score: 6/9 · Altman Z-Score: 7.41 · Beneish M-Score: -2.45
InvestSights quality score
74.9/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- EBITDA margin: guided 20%, delivered 20.1% (FY24) — exceeded guidance
- Pen-G production volume: guided 7,000–8,000MT/year, delivered 6,000MT/year (Q2 FY26) — missed guidance
Latest earnings call (Q1 FY27)
AI summary: The most important signal was management’s shift from discussing investment platforms qualitatively to laying out measurable monetisation milestones. The clearest example was TheraNym: Unit 1 qualification is planned by November 2026, validation batches in 2027 and steady revenue from 2028, while the combined Unit 1 and Unit 2 business was framed at US$150-200 million revenue…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.